Naproxen Norfri (Naproxen)

Naproxen works by non‑selectively blocking COX‑1 and COX‑2 enzymes, which reduces the production of prostaglandins. Lower prostaglandin levels diminish inflammation, decrease pain signalling, and reset the hypothalamic temperature set‑point, providing analgesic, anti‑inflammatory and antipyretic effects.

The appropriate dose of Naproxen Norfri is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of naproxen during pregnancy or lactation depends on the trimester and clinical necessity. It is generally avoided in the third trimester because of potential fetal complications. Breastfeeding mothers should consult a healthcare provider, as naproxen can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Naproxen has a longer half‑life than ibuprofen, allowing less frequent dosing for chronic conditions. Its anti‑inflammatory potency is comparable, but individual tolerance varies. All NSAIDs share similar risks of gastrointestinal, cardiovascular and renal adverse effects, so choice depends on patient‑specific factors.

Naproxen Norfri should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat and direct sunlight, and ensure the packaging remains tightly closed until use.

Naproxen Norfri is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may reduce gastrointestinal discomfort. The exact administration schedule should follow the prescriber’s directions.

The most serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, and severe renal impairment. Patients should be monitored for signs of bleeding, chest pain, or sudden changes in urine output, and seek medical attention promptly if they occur.

Individuals with a known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal ulcer disease, recent gastrointestinal bleeding, severe heart failure, or advanced renal or hepatic impairment should avoid using Naproxen Norfri. Pregnant women in the third trimester should also refrain from its use.